Contemporary Results and Clinical Utility of Renal Mass Biopsies in the Setting of Ablative Therapy: A single center experience

Lucy, X; Craig, Kiersten; Mosquera, Juan Miguel; Robinson, Brian D.; Scherr, Douglas; Pizzo, Joseph Del; McClure, Timothy; Khani, Francesca

doi:10.1016/j.ctarc.2020.100209

Cited by 4 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The proportion of non-diagnostic biopsies was low for local tumours >4 cm, but high for SRMs. The latter may be explained by the correlation between tumour size and the non-diagnostic RMB rate described in the literature [11, 12]. It may also be related to the improvement in ultrasonographic equipment and learning curve – the reduction of non-diagnostic RMBs of SRMs was however not significant.…”

Section: Discussionmentioning

confidence: 98%

Ultrasound-Guided Renal Mass Biopsy and Its Clinical Utility: A Single-Centre Experience

Jasiński¹,

Siekiera²,

Tworkiewicz³

2022

Urol Int

View full text Add to dashboard Cite

Introduction: Renal mass biopsy (RMB) is still underutilized, partially because many urologists argue that it does not substantially influence the management of renal masses. We sought to evaluate the influence of RMB on the management of renal tumours in our institution. Materials and Methods: A total of 387 RMBs performed at our institution from January 2016 to June 2020 were included. Patient demographics, mass size, biopsy result, and subsequent clinical management were retrospectively reviewed. Results: The mean mass size was 47.8 mm. Fifty-six percentage of tumours ≤40 mm (247) and 8% of tumours >40 mm (64) were biopsied. Seventy-six RMBs of disseminated tumours were performed. 14.9% of RMBs were non-diagnostic, and 27.1% of RMBs of tumours ≤40 mm were benign. The majority of tumours with first non-diagnostic RMB followed by histopathological verification were found to be malignant. There was significantly more conservative management and no radical nephrectomies in the benign biopsy group. One case of Clavien-Dindo grade ≥2 complication occurred. Conclusions: RMB result affects treatment decisions. Ultrasound-guided RMB is a safe procedure, and performing biopsies of tumours ≤40 mm may reduce the number of unnecessary interventions. Non-diagnostic RMBs should be repeated or treated as malignant.

show abstract

Section: Discussionmentioning

confidence: 98%

Ultrasound-Guided Renal Mass Biopsy and Its Clinical Utility: A Single-Centre Experience

Jasiński¹,

Siekiera²,

Tworkiewicz³

2022

Urol Int

View full text Add to dashboard Cite

show abstract

“…However, there is no sure way of predicting that renal masses are cancer by imaging alone. Tissue biopsy is a gold standard in many cancers; however, renal mass biopsy has significantly higher non-diagnostic rates and fails to aid in diagnosis ( 165 , 166 ). Approximately 20% of small renal masses (<4 cm) are non-malignant and do not need surgeries but still end up undergoing partial or full nephrectomy ( 167 ).…”

Section: Artificial Intelligence In Pmmentioning

confidence: 99%

Precision Medicine: An Optimal Approach to Patient Care in Renal Cell Carcinoma

et al. 2022

View full text Add to dashboard Cite

Renal cell cancer (RCC) is a heterogeneous tumor that shows both intra- and inter-heterogeneity. Heterogeneity is displayed not only in different patients but also among RCC cells in the same tumor, which makes treatment difficult because of varying degrees of responses generated in RCC heterogeneous tumor cells even with targeted treatment. In that context, precision medicine (PM), in terms of individualized treatment catered for a specific patient or groups of patients, can shift the paradigm of treatment in the clinical management of RCC. Recent progress in the biochemical, molecular, and histological characteristics of RCC has thrown light on many deregulated pathways involved in the pathogenesis of RCC. As PM-based therapies are rapidly evolving and few are already in current clinical practice in oncology, one can expect that PM will expand its way toward the robust treatment of patients with RCC. This article provides a comprehensive background on recent strategies and breakthroughs of PM in oncology and provides an overview of the potential applicability of PM in RCC. The article also highlights the drawbacks of PM and provides a holistic approach that goes beyond the involvement of clinicians and encompasses appropriate legislative and administrative care imparted by the healthcare system and insurance providers. It is anticipated that combined efforts from all sectors involved will make PM accessible to RCC and other patients with cancer, making a tremendous positive leap on individualized treatment strategies. This will subsequently enhance the quality of life of patients.

show abstract

Oncocytoma on renal mass biopsy: is it still the same histology when surgery is performed? Results from UroCCR-104 study

et al. 2023

View full text Add to dashboard Cite

Contemporary Results and Clinical Utility of Renal Mass Biopsies in the Setting of Ablative Therapy: A single center experience

Cited by 4 publications

References 27 publications

Ultrasound-Guided Renal Mass Biopsy and Its Clinical Utility: A Single-Centre Experience

Ultrasound-Guided Renal Mass Biopsy and Its Clinical Utility: A Single-Centre Experience

Precision Medicine: An Optimal Approach to Patient Care in Renal Cell Carcinoma

Oncocytoma on renal mass biopsy: is it still the same histology when surgery is performed? Results from UroCCR-104 study

Contact Info

Product

Resources

About